Prognosis of Myocarditis Developing After mRNA COVID-19 Vaccination Compared With Viral Myocarditis.

ABSTRACT:

Background

Association between messenger RNA (mRNA) COVID-19 vaccines and myocarditis has aroused public concern over vaccine safety.

Objectives

The goal of this study was to compare the prognosis of this condition with viral infection-related myocarditis over 180 days.

Methods

A territory-wide electronic public health care database in Hong Kong linked with population-based vaccination records was used to conduct a retrospective cohort study. Since the roll-out of BNT162b2 (Pfizer-BioNTech), patients aged ≥12 years hospitalized with myocarditis within 28 days after BNT162b2 vaccination were compared against viral infection-related myocarditis recorded before the pandemic (2000-2019), over a 180-day follow-up period (starting from diagnosis of myocarditis). All-cause m

SUBMITTER: Lai FTT 

PROVIDER: S-EPMC9721305 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature